Statins favorably stabilize coronary plaque. We evaluated the impact of statin use before the onset of acute myocardial infarction (AMI) on culprit lesion plaque morphology. Patients (n = 127) with AMI were divided into either a statin group (n = 31) or a nonstatin group (n = 96) based on statin use before the onset of AMI. Coronary plaque morphology of the culprit lesion was evaluated using intravascular ultrasound virtual histology (IVUS-VH) with radiofrequency data analysis before coronary intervention. The IVUS-VH identified 4 types of plaque components: fibrous, fibrofatty, dense calcium, and necrotic core. The IVUS-VH showed less percentage of necrotic area, greater percentage fibrous area, and greater percentage of fibrofatty area of the culprit lesion in the statin group. In conclusion, statin use before the onset of AMI might have effects on coronary plaque morphology of the AMI culprit lesion with less necrotic core and greater fibrous and fibrofatty component.
ShepherdJCobbeSMFordI, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333(20):1301–1307.
2.
NakamuraHArakawaKItakuraH; MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368(9542):1155–1163.
3.
. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389.
4.
SchwartzGGOlssonAGEzekowitzMD; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–1718.
5.
ZhouQLiaoJK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J. 2010;74(5):818–826.
6.
MinderCMBlahaMJHorneAMichosEDKaulSBlumenthalRS. Evidence-based use of statins for primary prevention of cardiovascular disease. Am J Med. 2012;125(5):440–446.
7.
KostisWJChengJQDobrzynskiJMCabreraJKostisJB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59(6):572–582.
8.
FukumotoYLibbyPRabkinE. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation. 2001;103(7):993–999.
9.
ReillySDLitovskySHSteinkampfMPCaulfieldJB. Statins improve human coronary atherosclerotic plaque morphology. Tex Heart Inst J. 2008;35(2):99–103.
10.
SchartlMBockschWKoschykDH. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation. 2001;104(4):387–392.
11.
OkazakiSYokoyamaTMiyauchiK. Early statin treatment in patientswith acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISHStudy. Circulation. 2004;110(9):1061–1068.
12.
ChiaSRaffelOCTakanoMTearneyGJBoumaBEJangIK. Association of statin therapy with reduced coronary plaque rupture: an optical coherence tomography study. Coron Artery Dis. 2008;19(4):237–242.
13.
SpencerFAAllegroneJGoldbergRJ, for the GRACE Investigators. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE Study. Ann Intern Med. 2004;140(11):857–866.
14.
IwakuraKItoHKawanoS. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J. 2006;27(5):534–539.
15.
YunKHShinISShinSN. Effect of previous statin therapy in patients with acute coronary syndrome and percutaneous coronary intervention. Korean Circ J. 2011;41:458–463.
16.
HikitaHKurodaSKawaguchiN. Differential characteristics of inflammatory responses to stent implantation between de novo and intrastent restenosis lesion in patients with stable angina. Angiology. 2012;63(2):92–95.
17.
NairAKubanBDTuzcuEMSchoenhagenPNissenSEVinceDG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation. 2002;106(17):2200–2206.
18.
NasuKTsuchikaneEKatohO. Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology. J Am Coll Cardiol. 2006;47(12):2405–2412.
NairAMargolisPKubanBDVinceDG. Automated coronary plaque characterization with intravascular ultrasound backscatter: ex vivo validation. EuroIntervention. 2007;3(1):113–120.
21.
OtsukaFHibiKKusamaI. Impact of statin pretreatment on the incidence of plaque rupture in ST-elevation acute myocardial infarction. Atherosclerosis. 2010;213(2):505–511.
22.
NissenSETuzcuEMSchoenhagenP, for the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1):29–38.
23.
NissenSENichollsSJSipahiI; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556–1565.
24.
Van der WalACBeckerAEvan der LoosCMDasPK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89(1):36–44.
25.
MizunoYJacobRFMasonRP. Inflammation and the development of atherosclerosis. J Atheroscler Thromb. 2011;18(5):351–358.
